Smith & Nephew (SN.) Stock Overview
Develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
SN. Community Fair Values
Create NarrativeSee what 62 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Smith & Nephew plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£11.47 |
| 52 Week High | UK£14.42 |
| 52 Week Low | UK£10.50 |
| Beta | 0.67 |
| 1 Month Change | 4.94% |
| 3 Month Change | -6.90% |
| 1 Year Change | 3.57% |
| 3 Year Change | -3.21% |
| 5 Year Change | -25.98% |
| Change since IPO | 5,686.85% |
Recent News & Updates
Analysis Article • May 31
We Ran A Stock Scan For Earnings Growth And Smith & Nephew (LON:SN.) Passed With Ease
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Narrative Update • May 11
SN.: Buybacks And New Medical Offerings Will Support Future Upside Potential
Analysts have made a small adjustment to the Smith & Nephew price target to reflect slightly different assumptions on fair value, discount rate, revenue growth, profit margin and future P/E, resulting in a marginal change that keeps the stock’s outlook broadly consistent with prior expectations. What's in the News Announced a new share repurchase program of up to US$500m, to be funded from free cash flow and existing cash balances, with a 12 month duration (Buyback Transaction Announcements).Recent updates
Analysis Article • May 31
We Ran A Stock Scan For Earnings Growth And Smith & Nephew (LON:SN.) Passed With Ease
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Narrative Update • May 11
SN.: Buybacks And New Medical Offerings Will Support Future Upside Potential
Analysts have made a small adjustment to the Smith & Nephew price target to reflect slightly different assumptions on fair value, discount rate, revenue growth, profit margin and future P/E, resulting in a marginal change that keeps the stock’s outlook broadly consistent with prior expectations. What's in the News Announced a new share repurchase program of up to US$500m, to be funded from free cash flow and existing cash balances, with a 12 month duration (Buyback Transaction Announcements).Narrative Update • Apr 20
SN.: New Wound And Orthopaedic Products Will Support Future Margin Expansion
Analysts have trimmed their price target for Smith & Nephew by about £0.19, reflecting slightly higher discount rate assumptions, a modest adjustment to revenue growth expectations, and a small uplift in long run profit margin and future P/E inputs. What's in the News The board proposes new Articles of Association, signaling an update to Smith & Nephew plc's corporate bylaws and governance framework (Changes in Company Bylaws/Rules).Narrative Update • Apr 01
SN.: New Product Launches And Capital Returns Will Support Future Margins
Analysts have nudged their price target for Smith & Nephew slightly higher to £14.30 from £14.30, reflecting small adjustments to their fair value estimate, discount rate, revenue growth assumptions, profit margin expectations, and a modestly lower future P/E multiple. What's in the News Launch of ALLEVYN COMPLETE CARE Foam Dressing with a five layer design aimed at both wound management and pressure injury prevention, initially in the US with further international launches planned for 2026 (Product related announcement).Narrative Update • Mar 18
SN.: Product Rollout And Capital Returns Will Support Future Margin Progress
Analysts have trimmed their price target on Smith & Nephew slightly to £14.30 from £14.31, reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E that keep the overall valuation broadly unchanged. What's in the News Launch of ALLEVYN COMPLETE CARE Foam Dressing, a five layer wound dressing designed for both wound management and pressure injury prevention, with plans to roll out beyond the US into European and other international markets in 2026 (Product related announcement).Narrative Update • Mar 04
SN.: Product Expansion And Capital Returns Will Support Measured Margin Progress
Analysts have lifted their price target for Smith & Nephew to £14.31 from £14.06, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News Showcasing handheld robotics, digital surgery tools and trauma products for hip, knee, shoulder and extremities at the AAOS Annual Meeting, including the CORI Surgical System and CORIOGRAPH pre operative planning and modeling services, plus expanded trauma offerings such as the EVOS LARGE & PERIPROSTHETIC Plating System, TRIGEN MAX Tibia Nailing System and new distribution deals with SI-BONE and RMR Ortho (Product related announcement) First CORI SHOULDER robotic shoulder arthroplasty procedures completed at Duke Health using the AETOS Shoulder System, with live demonstrations planned at AAOS in Booth #839 (Product related announcement) Board recommending a 2025 final dividend of 24.1 US cents per share, taking the total 2025 distribution to 39.1 US cents per share, described as a 4.3% increase from 2024 and aligned with a stated payout ratio of 35% to 40% (Dividend announcement) Company guidance for 2026 points to targets for further progress in revenue and profit for the full year, with expectations for a stronger second half compared to the first half for both revenue and profit, in line with what management describes as normal phasing (Corporate guidance) Completion of a share buyback tranche, with 28,320,469 shares repurchased for US$500m, stated as 3.24% of the company, under the programme announced on 5 August 2025 (Buyback update) Valuation Changes Fair Value: raised slightly from £14.06 to £14.31 per share.Narrative Update • Feb 18
SN.: Collaboration And M&A Focus Will Shape Margins And Operating Leverage
Analysts have made a small upward adjustment to their Smith & Nephew price target to £14.06, with the change reflecting updated assumptions for revenue growth, profit margins and future P/E expectations. What's in the News KARL STORZ North America and Smith & Nephew are collaborating to offer complementary visualization and sports medicine solutions for hospitals and ambulatory surgery centers, targeting multispecialty surgical environments with joint marketing where appropriate (Key Developments).Analysis Article • Jan 24
Do Smith & Nephew's (LON:SN.) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Narrative Update • Jan 10
SN.: Rising Margins And Operating Leverage Will Support Future Upside Potential
Analysts have nudged their price target for Smith & Nephew slightly lower to £14.05 from £14.09, citing updated assumptions around discount rates, revenue growth, margin outlook and future P/E multiples. What's in the News Smith & Nephew issued updated earnings guidance for 2025, indicating underlying revenue growth around 5% and a trading profit margin expected to be at least 19.5% within a 19.0% to 20.0% range, compared with a 2024 trading margin of 18.1% (Company guidance).Narrative Update • Dec 26
SN.: Expanding Trading Margins Will Drive Future Upside From Improved Operating Leverage
Analysts have trimmed their price target on Smith & Nephew slightly, to approximately $14.09 from about $14.43, citing a modestly higher discount rate and slightly lower long term profit margin expectations. These factors more than offset an improved revenue growth outlook and a marginally lower future P/E multiple.Analysis Article • Dec 23
Earnings Tell The Story For Smith & Nephew plc (LON:SN.)
With a price-to-earnings (or "P/E") ratio of 28.6x Smith & Nephew plc ( LON:SN. ) may be sending very bearish signals...Narrative Update • Dec 11
SN.: Expanding Trading Margins Will Drive Future Upside From New Devices
Analysts have trimmed their price target on Smith & Nephew slightly to reflect a modest recalibration of fair value, revenue growth and margin assumptions, while also factoring in a marginally higher future price to earnings multiple. This results in a small decrease in estimated equity value from approximately $14.50 to $14.43 per share.Analysis Article • Dec 10
Investors Will Want Smith & Nephew's (LON:SN.) Growth In ROCE To Persist
There are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll want...Narrative Update • Nov 27
SN.: Trading Margins Will Expand As New Devices Boost Profitability
Analysts have modestly raised their price target for Smith & Nephew from $14.37 to $14.50. This reflects incremental adjustments to fair value and slightly revised underlying financial assumptions.Analysis Article • Nov 13
Is Smith & Nephew plc (LON:SN.) Trading At A 21% Discount?
Key Insights The projected fair value for Smith & Nephew is UK£16.26 based on 2 Stage Free Cash Flow to Equity Current...Narrative Update • Nov 11
SN.: Trading Margins Will Improve After Recent Medical Device Launches
Analysts have raised their price target for Smith & Nephew slightly. The target has increased from $14.23 to $14.37, citing updated financial assumptions including modest improvements in profit margin and a slight increase in the projected discount rate.Narrative Update • Oct 28
Orthopaedic And Wound Care Advances Will Drive Global Reach And Clinical Outcomes
Analysts have slightly raised their price target for Smith & Nephew, increasing it from $14.21 to $14.23 due to minor adjustments to key valuation metrics and a modest uptick in forecasted discount rates. What's in the News New study shows Smith & Nephew's PICO sNPWT device significantly outperforms competitors in reducing wound complications, hospital stays, and healthcare costs in orthopedic and cardiovascular surgeries (Key Developments).Narrative Update • Oct 14
Orthopaedic Solutions And Wound Management Will Expand Global Reach
Analysts have raised their price target for Smith & Nephew from $13.85 to $14.21. This change reflects revised expectations around moderate revenue growth and profit margins, as well as a slightly higher discount rate.Analysis Article • Oct 14
Do Smith & Nephew's (LON:SN.) Earnings Warrant Your Attention?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysis Article • Sep 30
Is Smith & Nephew (LON:SN.) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Narrative Update • Sep 19
Orthopaedic Solutions And Wound Management Will Expand Global Reach
The significant drop in Smith & Nephew’s future P/E ratio suggests improving earnings expectations or a lower valuation premium, which supports the slight increase in the consensus analyst price target from £13.61 to £13.85. What's in the News AAOS guidelines now strongly recommend Smith & Nephew's REGENETEN Bioinductive Implant for rotator cuff repair, citing significantly lower re-tear rates and improved patient outcomes; new US indication covers extra-articular ligament injuries, expanding the addressable market.Analysis Article • Aug 28
We Like These Underlying Return On Capital Trends At Smith & Nephew (LON:SN.)
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Analysis Article • Aug 12
We Think Smith & Nephew's (LON:SN.) Robust Earnings Are Conservative
Smith & Nephew plc ( LON:SN. ) recently posted some strong earnings, and the market responded positively. We did some...Analysis Article • Aug 08
Smith & Nephew plc Just Beat EPS By 26%: Here's What Analysts Think Will Happen Next
Shareholders of Smith & Nephew plc ( LON:SN. ) will be pleased this week, given that the stock price is up 16% to...Narrative Update • Aug 07
Orthopaedic Solutions And Wound Management Will Expand Global Reach
Smith & Nephew's consensus analyst price target has risen to £13.30, reflecting a lower expected future P/E and slightly stronger revenue growth forecasts. What's in the News Smith+Nephew launched the Q-FIX KNOTLESS All-Suture Anchor, featuring market-leading fixation strength, proprietary suture lock mechanism, and streamlined suture shuttling for various joint repairs.Analysis Article • Aug 04
Estimating The Fair Value Of Smith & Nephew plc (LON:SN.)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Smith & Nephew fair value estimate is UK£13.43 Smith...Analysis Article • Jun 27
Smith & Nephew plc's (LON:SN.) Popularity With Investors Is Clear
Smith & Nephew plc's ( LON:SN. ) price-to-earnings (or "P/E") ratio of 32.1x might make it look like a strong sell...
New Narrative • Mar 15
Restructuring Will Improve Operating Efficiency By 2025
Strategic restructuring and innovative platforms like CORI and REGENETEN are enhancing revenue growth and operational efficiency, impacting margins positively as macroeconomic conditions stabilize.Shareholder Returns
| SN. | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 4.7% | 4.3% | -0.1% |
| 1Y | 3.6% | -8.6% | 16.7% |
Return vs Industry: SN. exceeded the UK Medical Equipment industry which returned -9.7% over the past year.
Return vs Market: SN. underperformed the UK Market which returned 16.7% over the past year.
Price Volatility
| SN. volatility | |
|---|---|
| SN. Average Weekly Movement | 3.4% |
| Medical Equipment Industry Average Movement | 5.8% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in GB Market | 11.6% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: SN. has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: SN.'s weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1856 | 16,988 | Deepak Nath | www.smith-nephew.com |
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Smith & Nephew plc Fundamentals Summary
| SN. fundamental statistics | |
|---|---|
| Market cap | UK£9.80b |
| Earnings (TTM) | UK£468.59m |
| Revenue (TTM) | UK£4.62b |
20.9x
P/E Ratio2.1x
P/S RatioIs SN. overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SN. income statement (TTM) | |
|---|---|
| Revenue | US$6.16b |
| Cost of Revenue | US$1.96b |
| Gross Profit | US$4.21b |
| Other Expenses | US$3.58b |
| Earnings | US$625.00m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Aug 04, 2026
| Earnings per share (EPS) | 0.73 |
| Gross Margin | 68.25% |
| Net Profit Margin | 10.14% |
| Debt/Equity Ratio | 58.8% |
How did SN. perform over the long term?
See historical performance and comparisonDividends
2.6%
Current Dividend Yield54%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/08 04:11 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Smith & Nephew plc is covered by 34 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sally Taylor | Barclays |
| Hassan Al-Wakeel | Barclays |
| Samuel England | Berenberg |